Novo Nordisk's reimbursement appeal goes unheard, Sanofi insulin deemed equivalent
The Danish Medicines Agency's Reimbursement Committee has decided to ignore Novo Nordisk's pleas to leave the company's general reimbursement scheme untouched. Instead, it recommends other fast-acting insulins for new patients.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
The Danish Medicines Agency has received the Reimbursement Committee's final recommendation for a revision pertaining to the reimbursement scheme for insulin products – and it doesn't bode well for Novo Nordisk.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
